Inhalation solutions and suspensions manufacturer Nephron Pharmaceuticals has announced plans for a $215 million expansion at its South Carolina, USA facilities, including office, warehouse and vaccine production space. In addition to manufacturing its own products, Nephron also offers contract manufacturing services for sterile pharmaceutical products. The expansion is expected to create almost 400 new full-time positions by 2024.
Earlier this year, Nephron CEO Lou Kennedy told reporters that demand for the company’s inhalation products — including albuterol, ipratroprium bromide, and budesonide — was up by almost 50% over normal levels due to the COVID-19 pandemic. She said at the time that she planned to meet with the FDA regarding plans for additional production lines.
In the announcement of the expansion plans, Kennedy commented, “Our team is extraordinarily grateful for the opportunity to grow in South Carolina. Thanks to our partnerships with state and local officials, and the trust they have placed in us, we have been able to provide life-saving medications to patients around the world and establish ourselves as the global leader in what we do. We are proud of these achievements and more, and we know our best days are ahead of us. That is what makes this latest announcement so special.”
Read the Nephron Pharmaceuticals press release.
